重症监护室连续性肾脏替代治疗后未拔除导管患者不同肝素封管频率比较:中国一项前瞻性开放标签随机对照试验方案
本研究为在中国武汉大学中南医院开展的前瞻性、开放标签、平行组、单中心、优效性随机对照试验,计划纳入390例ICU内CRRT后未拔除透析导管的患者,按1:1随机分为干预组(n=195)和对照组(n=195)。对照组每24小时肝素封管一次,干预组每72小时封管一次,两组均使用1000 U/mL肝素溶液(0.8 mL肝素+4.2 mL生理盐水)。主要结局为导管功能障碍发生率和导管生存时间。
要点
- 拟纳入390例ICU内CRRT后未拔除透析导管的患者,1:1随机分为每24小时封管组和每72小时封管组。
- 两组均使用1000 U/mL肝素溶液(0.8 mL肝素+4.2 mL生理盐水)封管,对照组每24小时一次,干预组每72小时一次。
- 主要结局为导管功能障碍发生率和导管生存时间,同时评估安全性及成本效果。
核心结论
- 该研究旨在比较每24小时与每72小时肝素封管频率对ICU内CRRT后未拔除透析导管患者导管功能障碍发生率的影响,并评估维持导管通畅、预防导管相关血流感染及成本效果。
研究设计与样本
- 前瞻性、开放标签、平行组、单中心、优效性随机对照试验,在武汉大学中南医院开展。
- 计划纳入390例合格患者,按1:1比例随机分配至干预组(n=195)或对照组(n=195)。
- 纳入标准:ICU内CRRT后未拔除透析导管;年龄≥18岁,性别不限;预期导管留置时间≥72小时;患者或其法定代理人签署知情同意书。
- 排除标准:入组前已存在导管功能障碍或感染;研究期间实际拔除导管;过去两个月内参与其他干预性研究。
- 不采用分层变量,使用简单随机化;由武汉大学中南医院重症医学科研究团队(包括主治医师、护士长和研究护士)负责招募。
主要发现
- 该文为试验方案,未报告研究结果。
关键数值与推荐
- 对照组每24小时肝素封管一次直至拔除导管,干预组每72小时封管一次。
- 两组均使用1000 U/mL肝素溶液(0.8 mL肝素+4.2 mL生理盐水)作为封管液。
- 主要结局:导管功能障碍发生率和导管生存时间。
- 安全性终点:穿刺点出血(持续渗血、局部血肿)、导管相关血流感染、非计划性拔管和空气栓塞等不良事件的发生率。
- 成本效果结局:两组的总医疗费用(包括检查费、治疗费、材料费、药物费、护理劳务费)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the impact of different heparin locking frequencies on the incidence of catheter dysfunction among patients with unremoved dialysis catheters after continuous renal replacement therapy (CRRT) in the Intensive Care Unit (ICU) of Wuhan, China. The study aims to identify a relatively low-risk locking frequency for catheter dysfunction, evaluate its effects on maintaining catheter patency and preventing catheter-related bloodstream infections (CRBSI), and determine the optimal locking strategy that balances infection risk and catheter functionality. And conduct a cost-effectiveness analysis to assess the economic value of different locking frequencies, including total medical costs. METHODS: This is a prospective, open-label, parallel-group, single-center, superiority randomized controlled trial conducted at Zhongnan Hospital of Wuhan University. A total of 390 eligible patients will be enrolled and randomly assigned in a 1:1 ratio to either the intervention group (n = 195) or the control group (n = 195). INCLUSION CRITERIA: ① Patients with an unremoved dialysis catheter post-CRRT in the ICU; ② Age ≥ 18 years, regardless of gender; ③ Expected catheter indwelling time ≥ 72 h; ④ Signed informed consent by the patient or their legal representative. EXCLUSION CRITERIA: ① Pre-existing catheter dysfunction or infection before enrollment; ② Actual catheter removal during the study period; ③ Participation in another interventional study within the past two months. No stratification variables are used; simple randomization will be applied. Recruitment will be managed by the research team from the Department of Critical Care Medicine at Zhongnan Hospital of Wuhan University, including attending physicians, head nurses, and research nurses. The control group will receive heparin locking every 24 h until catheter removal, while the intervention group will be locked every 72 h. Both groups will use 1000 U/mL heparin solution (0.8 mL heparin + 4.2 mL normal saline) as the locking agent. PRIMARY OUTCOMES: Incidence of catheter dysfunction and catheter survival time. Safety endpoints: Rates of adverse events such as bleeding at the puncture site (persistent oozing, local hematoma), CRBSI, unplanned extubation, and air embolism. Cost-effectiveness outcomes: Total medical costs (including examination fees, treatment fees, material fees, medication fees, nursing labor costs) between the two groups. Outcome assessors and data analysts will be blinded. All analyses will follow the intention-to-treat principle based on randomized allocation, with missing data for primary outcomes excluded. DISCUSSION: This study represents the first prospective RCT comparing 24-h versus 72-h heparin locking frequencies in ICU patients with unremoved dialysis catheters post-CRRT. The findings are expected to provide high-quality evidence for selecting optimal catheter maintenance strategies, reducing nursing workload, and lowering healthcare costs for patients. In addition to clinical efficacy and safety, the integrated cost-effectiveness analysis will provide evidence for the economic feasibility of optimal locking strategies, supporting resource allocation decisions in clinical practice. TRIAL REGISTRATION {4}: Chinese Clinical Trial Registry. ChiCTR2500107820 . September 1, 2025.
引用
- Zhang Y, Ma J, Liu C, et al. Comparison of different heparin locking frequencies in patients with unremoved catheters after continuous renal replacement therapy in the intensive care unit: a prospective, open-label, randomized controlled trial protocol from China. Trials. 2026. PMID: 41588545. doi:10.1186/s13063-026-09475-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。